Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SILO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSilo Pharma completes 1-for-15 reverse stock split to boost share price
Filed June 3, 2026 · Period ending June 1, 2026 · ~1 min read
Key Changes
-
high
Reverse stock split became effective June 2, 2026 at 4:01 p.m. ET, with every 15 shares combined into 1 share. Split-adjusted trading began June 3 on Nasdaq under ticker SILO with new CUSIP 82711P 300.
Item 5.03: Reverse Stock Split verify on EDGAR → -
medium
Authorized shares reduced proportionately to 6,666,667 shares while par value remains $0.0001 per share, maintaining the same ratio of authorized to outstanding shares as before the split.
Item 5.03: Authorized Shares verify on EDGAR → -
medium
All outstanding stock options, warrants, and equity plan reserves adjusted proportionately—exercise prices increased 15x while share counts decreased by factor of 15, preserving economic value for holders.
Item 5.03: Equity Awards verify on EDGAR → -
low
Fractional shares resulting from the split were rounded up to the next whole share, providing a small benefit to shareholders whose holdings weren't evenly divisible by 15.
Item 5.03: Fractional Shares verify on EDGAR → -
medium
Active S-1 and S-3 registration statements automatically updated to reflect proportionate reduction in registered shares under Rule 416(b) of the Securities Act.
Item 8.01: Registration Statements verify on EDGAR →
Summary
Silo Pharma executed a 1-for-15 reverse stock split effective June 2, 2026, consolidating every 15 shares into one. The company's stock began trading on a split-adjusted basis June 3 on Nasdaq under the same ticker symbol SILO but with a new CUSIP identifier.
Reverse splits are typically implemented to increase per-share price, often to maintain compliance with exchange minimum bid price requirements or to improve institutional investor appeal. For existing shareholders, the split doesn't change the aggregate value of holdings—if you owned 150 shares worth $1 each before the split, you now own 10 shares worth $15 each.
The company proportionately reduced authorized shares to 6,666,667 and adjusted all outstanding options and warrants to maintain their economic value. Fractional shares were rounded up, providing a minor benefit to some holders. Retail investors should monitor whether the higher share price achieves its intended goal—watch for any Nasdaq compliance notices in future filings and track whether the stock maintains its post-split price level or experiences further decline. The company's active registration statements remain in place with proportionately fewer shares registered for potential future offerings.
Section-by-Section Diff
Event · Item 3.03 — Material Modification to Rights of Security Holders
8-K filing references Item 3.03 regarding material modification to rights of security holders, but no substantive disclosure text provided.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Item 3.03. Material Modification to Rights of Security Holders.
To the extent required by Item 3.03 of Form 8-K, the information contained in
The 8-K filing invokes Item 3.03, which typically covers material modifications to the rights of security holders such as changes to charter documents, preferred stock terms, or other rights affecting shareholders. However, the filing text appears incomplete or truncated, providing no substantive details about what modification occurred or cross-referencing other sections for the actual disclosure.
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
Silo Pharma completed a 1-for-15 reverse stock split effective June 2, 2026, reducing authorized shares and adjusting outstanding equity awards.
Added in current filing · verify on EDGAR →
On June 1, 2026, Silo Pharma, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”). The Reverse Stock Split became effective at 4:01 p.m., Eastern Time, on Tuesday, June 2, 2026, and the Company’s Common Stock began trading on a split-adjusted basis when The Nasdaq Stock Market (“Nasdaq”) opened on June 3, 2026.
The company executed a 1-for-15 reverse stock split, meaning every 15 shares of common stock were combined into 1 share. The split became effective June 2, 2026 at 4:01 p.m. ET, with split-adjusted trading beginning June 3, 2026 on Nasdaq. Reverse splits are often used to increase share price to maintain exchange listing requirements or improve market perception.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company’s Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol “SILO”, but the security has been assigned a new CUSIP number (82711P 300).
While the ticker symbol remains "SILO" on Nasdaq Capital Market, the stock received a new CUSIP identifier (82711P 300) to distinguish the post-split shares from pre-split shares for clearing and settlement purposes.
Event · Item 8.01 — Other Events
Silo Pharma disclosed a 1-for-15 reverse stock split, reducing registered shares proportionately across active S-1 and S-3 registration statements.
Added in current filing · verify on EDGAR →
Pursuant to Rule 416(b) under the Securities Act of 1933, as amended, the amount of undistributed shares of Common Stock deemed to be covered by the effective registration statements of the Company described above are proportionately reduced as of the effective time of the Reverse Stock Split at the 1-15 Reverse Stock Split ratio, giving effect to the Reverse Stock Split.
The company executed a 1-for-15 reverse stock split, meaning every 15 existing shares are consolidated into 1 share. This proportionately reduces the number of shares registered under the company's active S-1 and S-3 registration statements. Reverse splits are typically used to increase share price to meet exchange listing requirements or improve marketability.
Added in current filing · verify on EDGAR →
The Company has a registration statements on Form S-1 (File Nos. 333-280855 and 333-291129) and a registration statements on Form S-3 (File Nos. 333-276658) on file with the SEC.
The company confirms it has active registration statements on file (two S-1 forms and one S-3 form) that allow it to offer and sell securities. The reverse stock split information is being incorporated by reference into these registration statements, automatically updating them without requiring new filings.
Event · Item 9.01 — Financial Statements and Exhibits
Silo Pharma filed a Certificate of Change with no material business impact disclosed in the 8-K body.
Added in current filing · verify on EDGAR →
Exhibit Description
3.1 Certificate of Change
The company filed a Certificate of Change as Exhibit 3.1. The 8-K body provides no details about what was changed (e.g., authorized shares, par value, name change). Without the exhibit content, the materiality and investor impact cannot be assessed.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify